Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Klaus Kraemer is active.

Publication


Featured researches published by Klaus Kraemer.


Metabolism-clinical and Experimental | 2003

Interactions of conjugated linoleic acid and lipoic acid on insulin action in the obese Zucker rat.

Mary K. Teachey; Zachary Taylor; Thomas Maier; Vitoon Saengsirisuwan; Julie A. Sloniger; Stephan Jacob; Martin Jochen Klatt; Arne Ptock; Klaus Kraemer; Oliver Hasselwander; Erik J. Henriksen

The fatty acid conjugated linoleic acid (CLA) and the antioxidant R-(+)-alpha-lipoic acid (R-ALA) individually enhance glucose tolerance and insulin action on skeletal muscle glucose transport in the insulin-resistant obese Zucker rat. To date, no study has assessed the potential interactions between these 2 interventions in treating insulin resistance. The present study was designed to determine whether chronic treatment with CLA and R-ALA in combination would enhance skeletal muscle glucose transport to a greater extent than either intervention individually. CLA, R-ALA, or a combination treatment of R-ALA and CLA were administered to female obese Zucker rats for 20 days at low or high doses. Whereas low-dose R-ALA (10 mg/kg body weight) alone did not alter muscle glucose transport, low-dose CLA (0.3 g/kg) induced a significant increase (38%, P <.05) in insulin-mediated glucose transport in epitrochlearis, but not in soleus. Low-dose combination therapy brought about the greatest enhancement of insulin-mediated glucose transport in epitrochlearis (77%) and soleus (54%), with the latter effect being associated with a 50% reduction in protein carbonyls (an index of tissue oxidative stress) and a 33% diminution in muscle triglycerides. High-dose treatments with CLA (1.5 g/kg), R-ALA (50 mg/kg), and the combination of CLA and R-ALA elicited increases in insulin-mediated glucose transport in epitrochlearis (57%, 58%, and 77%) and soleus (32%, 35%, and 54%). However, whereas the individual high-dose treatments with CLA and R-ALA reduced protein carbonyls (63% and 49%) and triglycerides (29% and 28%) in soleus, no further reductions were observed with the high-dose combination treatment groups. These findings support a significant interaction between low doses of CLA and R-ALA for enhancement of insulin action on skeletal muscle glucose transport, possibly via reductions in muscle oxidative stress and in lipid storage.


Lipids | 2004

Effects of specific conjugated linoleic acid isomers on growth characteristics in obese Zucker rats

S.R. Sanders; Mary K. Teachey; Arne Ptock; Klaus Kraemer; Oliver Hasselwander; Erik J. Henriksen; L. H. Baumgard

Growing female obese Zucker (fa/fa) rats were treated (via intragastric gavage) for 21 d with either a (i) vehicle [corn oil; 0.9 g/kg body weight (BW)], (ii) CLA mixture [50∶50; trans-10,cis-12 and cis-9,trans-11 CLA], (iii) cis-9,trans-11 CLA, or (iv) trans-10,cis-12 CLA (CLA treatments at 1.5 g CLA/kg BW). Compared with controls, average daily gain (g/d) was reduced 24 and 44% by the CLA mixture and trans-10,cis-12 CLA, respectively There was no treatment effect on average whole-body (minus heart and liver) composition (dry matter basis): fat (70.2%), protein (21.0%), and ash (4.3%). Compared with animals treated with cis-9,trans-11 CLA, obese Zucker rats treated with trans-10,cis-12 and the CLA mixture had 7.8% more carcass water. Treatment had no effect on heart or liver weights or on heart or liver weights as a percentage of body weight, but compared with the other treatments trans-10,cis-12 CLA increased liver lipid contentby 33%. Hepatic lipid ratios of 16∶1/16∶0 and 18∶1/18∶0 (a proxy for Δ9-desaturase capability) were not affected by treatment (0.1 and 0.6, respectively). Simlar to previous reports, CLA increased hepatic lipid content and altered both liver and carcass FA composition (i.e., reduced arachidonic acid content), but the ability of CLA to manipulate body composition in obese Zucker rats remains questionable.


Archive | 2000

Composition used as folate source in food, feed, nutritional supplements or medicaments, e.g. for prophylaxis of cardiovascular disease includes folic acid and 5-methyl-tetrahydrofolic acid

Wolfgang Haehnlein; Klaus Kraemer; Oliver Hasselwander; Loni Schweikert


Archive | 2001

Food, nutritional supplement, feed or medicament preparations containing conjugated cis/trans-octatrienoic acid, useful e.g. for reducing food intake, improving food utilization or treating cancer or diabetes

Klaus Kraemer; Oliver Hasselwander; Uwe Oberfrank


Archive | 2005

Verwendung von ammoniumsalze der liponsäure zur behandlung diabetischer störungen

Klaus Kraemer; Frank Haunert; Markus Matuscheck; Oliver Hasselwander; Martin Jochen Klatt


Archive | 2002

A process for preparing crystalline choline ascorbate

Ludwig Voelkel; Alfred Oftring; Oliver Hasselwander; Ulrike Sindel; Klaus Kraemer


Archive | 2002

Verfahren zur Herstellung von kristallinem Cholinascorbat A process for preparing crystalline choline ascorbate

Ludwig Voelkel; Alfred Oftring; Oliver Hasselwander; Ulrike Sindel; Klaus Kraemer


Archive | 2002

Zubereitung zur verbesserung der nahrungsverwertung

Oliver Hasselwander; Klaus Kraemer; Uwe Oberfrank


Archive | 2001

Combination of lipoic acid and konjuensyrer for the treatment of diabetic disorders

Oliver Hasselwander; Kai-Uwe Baldenius; Klaus Kraemer; Martin Jochen Klatt; Loni Schweikert


Archive | 2001

Kombination von liponsäure und c1-donoren zur behandlung von störungen des zentralen nervensystems

Guenther P Eckert; Wolfgang Haehnlein; Oliver Hasselwander; Klaus Kraemer; Walter E Mueller

Collaboration


Dive into the Klaus Kraemer's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge